Liver B Cells and MASLD Progression
Author Information
Author(s): Jiang Su, Lu Jiaxue, Li Nan, Bai Xueqi, Shi Lei, Tian Ziying, Zhou Jieyu, Zhang Wenling
Primary Institution: The Third Xiangya Hospital, Central South University, Changsha, Hunan, China
Hypothesis
The apelin/APLNR axis plays a crucial role in the progression of metabolic dysfunction-associated steatotic liver disease (MASLD).
Conclusion
The apelin/APLNR axis is crucial in MASLD progression, and targeting this axis may offer therapeutic potential.
Supporting Evidence
- Apelin and APLNR levels were higher in MASLD patients compared to normal individuals.
- Animal models showed that apelin injections increased liver steatosis and fibrosis.
- RNA sequencing indicated that the apelin/APLNR axis promotes inflammatory cytokine expression.
Takeaway
This study found that a substance called apelin helps liver B cells, which can make a liver disease called MASLD worse.
Methodology
The study used serum samples from MASLD patients, liver tissues from hepatocellular carcinoma patients, and mouse models to investigate the apelin/APLNR axis.
Limitations
The study primarily focused on mouse models, which may not fully replicate human disease.
Participant Demographics
74 MASLD patients and 14 normal individuals were included in the serum analysis.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website